Combination of Iodine-125 brachytherapy and chemotherapy for locally recurrent stage III non-small cell lung cancer after concurrent chemoradiotherapy

BMC Cancer

Research Article

Xiaojuan Yu¹  Jingdong He¹  Jin Li¹  Xiaoming Zhong¹ 

[1] Department of Oncology, Huai’an First People’s Hospital, Nanjing Medical University, 6 Beijing Road West, 223300, Huai’an, Jiangsu, China;

关键词: Brachytherapy;    Iodine-125;    Non-small cell lung cancer;    Recurrence;   

DOI  :  10.1186/s12885-015-1657-3

 received in 2015-07-10, accepted in 2015-09-27,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundLocally recurrent non-small cell lung cancer (NSCLC) poses a great challenge to physicians. This study aimed to explore the efficacy and safety of the combination of brachytherapy and docetaxel and cisplatin for the treatment of locally recurrent stage III NSCLC.MethodsFifty two patients with locally recurrent stage III NSCLC after concurrent chemoradiotherapy were randomly divided into two groups (n = 26). The patients in experimental group were treated with implantation of radioactive 125I seeds and DP regimen (docetaxel 60 mg/m2/cisplatin 75 mg/m2). Patients in control group received DP chemotherapy. The local control rate (LCR), progression-free survival (PFS), and overall response rate (ORR) were defined according to the Response Evaluation Criteria in Solid Tumors (RECIST).ResultsWith a median follow-up time of 11 months, PFS and LCR was 8 months (95 % CI: 6.99–9.01 months) vs. 5.5 months (95 % CI: 4.43–6.57 months) (P < 0.05) and 10 months (95 % CI: 8.72–11.28 months) vs. 6.2 months (95 % CI: 5.27–7.13 months) (P < 0.05) in the experimental and control groups, respectively. The ORR did not differ between treatment groups and was noted to be 69.2 % and 57.7 %, respectively (P >0.05). There was no occurrence of severe complications in experimental and control groups.ConclusionThe combination of 125I brachytherapy and second-line chemotherapy is superior to chemotherapy alone and is an effective and safe therapy for this disease.Trial registration numberChiCTR-IOR-15006560

【 授权许可】

CC BY   
© Yu et al. 2015